NIAID Offering $10.3M for Pathogen Dx, Therapeutics | GenomeWeb

NEW YORK (GenomeWeb News) – The National Institute of Allergy and Infectious Diseases plans to grant up to $10.3 million in fiscal 2010 to fund research partnerships focused on developing diagnostics and therapeutics for drug-resistant bacteria and eukaryotic parasites.

NIAID will fund a range of research approaches for NIAID Category A, B, or C bacteria or eukaryotic parasites, as well as development of diagnostics or therapeutics against non-listed organisms for which naturally-occurring drug resistance is a growing clinical problem.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: nasal microbial communities in asthma patients; sequencing-based way to detect, track schistosomiasis; and more.

The New York Times speaks with Vanderbilt's John Anthony Capra about Neanderthal genes in modern humans.

A draft guidance from the FDA suggests the agency wants to more tightly control gene-edited animals, according to Technology Review.

Researchers were among this weekend's protesters bemoaning the new US administration, Vox reports.